Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to increase the body’s own production and release of growth hormone (GH), which subsequently increases insulin-like growth factor-1 (IGF-1).

Unlike many experimental peptides, tesamorelin has substantial human clinical research behind it. An FDA-approved tesamorelin medicine is indicated specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not FDA-approved as a general weight-loss treatment.

Key Research Areas

Visceral Fat Research
Tesamorelin is particularly well studied for its effects on visceral adipose tissue (VAT) — the metabolically active fat located around internal abdominal organs.

Large randomized clinical trials found significant reductions in visceral abdominal fat compared with placebo. A pooled analysis of Phase III trials reported an approximately 15% treatment effect on VAT after 26 weeks, with reductions maintained during continued treatment.

Growth Hormone & IGF-1 Signalling
Tesamorelin stimulates endogenous GH secretion through the GHRH receptor, rather than supplying growth hormone directly. Increased GH signalling subsequently increases circulating IGF-1.

Clinical trials have demonstrated substantial increases in IGF-1 during tesamorelin treatment.

Body Composition Research
Research has investigated tesamorelin’s ability to alter body-fat distribution. Importantly, clinical studies found reductions in visceral abdominal fat without equivalent reductions in abdominal subcutaneous fat, suggesting a relatively selective effect on visceral adiposity.

Metabolic Research
Tesamorelin has also been investigated for its effects on metabolic markers including:

• Triglycerides
• Cholesterol
• Glucose metabolism
• Insulin sensitivity
• Visceral adiposity
• Liver fat

Clinical research has reported improvements in visceral fat and certain lipid measurements, while another randomized trial demonstrated reductions in both visceral and liver fat.

Liver Fat Research
Tesamorelin has generated additional research interest because studies in people with HIV have demonstrated reductions in hepatic (liver) fat alongside reductions in visceral abdominal fat.

How Tesamorelin Works

Tesamorelin mimics the action of naturally occurring GHRH.

The basic pathway is:

Tesamorelin → GHRH receptor → Pituitary GH release → Increased IGF-1 signalling

Because it stimulates endogenous growth-hormone secretion, its mechanism differs from directly administering recombinant human growth hormone.

Research involving this pathway has focused on:

• Visceral fat metabolism
• Growth hormone secretion
• IGF-1 signalling
• Body composition
• Lipid metabolism
• Liver fat
• Metabolic function

Tesamorelin vs CJC-1295

Although both peptides interact with the growth hormone-releasing pathway, they should not be treated as interchangeable compounds.

Tesamorelin has undergone extensive controlled human clinical trials and has an FDA-approved pharmaceutical formulation for a specific medical indication.

CJC-1295 remains primarily an investigational peptide and does not have the same level of clinical evidence or regulatory approval.